Nephrocare IPO: Consolidated Surge Hides Standalone Loss Post Listing

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Nephrocare IPO: Consolidated Surge Hides Standalone Loss Post Listing
Overview

Nephrocare Health Services, post-IPO, reported robust consolidated Q3 FY26 revenue up 31.68% to ₹2,597.29M and PAT up 60.33% to ₹322.40M. However, standalone performance showed a stark contrast, with PAT turning negative at -₹189.48M for 9M FY26, largely due to a ₹371.89M non-recurring finance cost.

Nephrocare's Post-IPO Debut: Consolidated Strength Masks Standalone Woes Amidst ₹371.89M Finance Cost

Nephrocare Health Services Limited, marking its first financial disclosure post-listing on the BSE and NSE on December 17, 2025, presented a mixed financial performance for the quarter and nine months ended December 31, 2025.

The Numbers

  • Standalone Performance (Q3 FY26): Revenue from operations grew by 16.25% YoY to ₹1,606.64 million. Profit After Tax (PAT) saw a modest increase of 4.15% YoY to ₹84.52 million. Basic Earnings Per Share (EPS) stood at ₹0.90, a 10% decrease YoY.
  • Standalone Performance (9M FY26): A significant swing occurred, with PAT turning negative at -₹189.48 million, a sharp contrast to the ₹285.64 million reported in the prior year's nine-month period (9M FY25). Basic EPS for 9M FY26 was -₹2.17 (compared to ₹3.53 in 9M FY25).
  • Consolidated Performance (Q3 FY26): Revenue from operations surged by 31.68% YoY to ₹2,597.29 million. Consolidated PAT increased substantially by 60.33% YoY, reaching ₹322.40 million. Consolidated basic EPS was ₹3.43, up 38.87% YoY.
  • Consolidated Performance (9M FY26): Consolidated PAT was ₹464.70 million, up 10.04% YoY from ₹422.29 million in 9M FY25. Consolidated basic EPS was ₹5.32.

The Quality & The Grill

A critical factor impacting the standalone 9M FY26 results was a significant non-cash, non-recurring finance cost of ₹371.89 million. This cost is related to financial liabilities measured at fair value through profit or loss (FVTPL), as detailed in the financial statements. While this item substantially contributed to the negative PAT for the nine-month standalone period, the absence of specific management guidance or commentary on future outlook in the announcement leaves investors seeking clarity.

Risks & Outlook

The primary concern for investors post-IPO is the stark divergence between consolidated and standalone performance. The negative standalone PAT, driven by the ₹371.89 million FVTPL finance cost, raises questions about the sustainability of standalone profitability and the management of financial liabilities. Although this cost is noted as non-recurring, the lack of detailed management outlook or specific guidance means investors must closely monitor future disclosures for further clarification. The company also announced the designation of Mr. Ravindra Tiwari as Senior Management Personnel, a governance update.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.